Skip to main content

Table 3 Health and economic parameters used in the cost-effectiveness analysis

From: Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis

  Parameter Mean value (95% CI where applicable) Reference
T Time horizon 10 years
r Discount rate 3.5% [7]
Probability of clinical outcomes
rGa Per-infection probability of GP consultation 0–4 years: 0.006–0.065 [41]
5–14 years: 0.017–0.018 [44]
15+ years: 0.014–0.132 [42]
 rDa Per-infection probability of death 0–4 years: 8.197 × 10−6–3.698 × 10−5 [41]
5–14 years: 6.731 × 10−6–6.896 × 10−6 [44]
15+ years: 4.663 × 10−6–0.002 [42]
rHa,r Per-infection probability of hospital admissions VHR, 0–8 months: 0.133–0.391 [57]
HR, 0–11 months: 0.013–0.130 [46]
NR, 0–11 months: 0.010–0.097 [46]
NR, 1–4 years: 0.004–0.008 [29]
NR, 5–64 years: 4.688 × 10−5–8.004 × 10−5 [44]
NR, 65+ years: 6.197 × 10−5–0.019 [42]
rBa,r Number of hospital bed days per hospitalisation VHR, 0–8 months: 8–25 [57]
HR, 0–11 months: 5–7 [46]
NR, 0–11 months: 1–5 [46]
NR, 1–64 years: 2 [47]
NR, 65+ years: 3 [48]
Costs
Per GP visit
  ΘGP All ages £36.00 (fixed) [53, 54]
Per hospital bed day
  ΘaH Paediatric (< 5 years of age) £725.29 (718.13–733.99)1 [56]
  ΘaH Adult (≥ 5 years of age) £425.24 (415.16–435.70)2 [56]
Administration of prophylactics (per course)
  Δpal Palivizumab £57.50 (fixed) [54]
  Δmab La-mABs £11.00 (fixed) [54]
  Δmat Maternal vaccine £9.00 (fixed) [54]
  Δvac Vaccine £9.00 (fixed) [54]
Purchasing prices (per course)
  ρpal Palivizumab £4035.50 (fixed) [56]
  ρX La-mABs, Maternal vaccine and vaccine Not known  
QALY loss
Symptomatic infection
  QaS Paediatric (< 5 years of age) 2.336 × 10−3 (0.269 × 10−3–9.255 × 10−3)3 [52]
  QaS Adult (≥5 years of age) 1.448 × 10−3 (0.135 × 10−3–5.928 × 10−3)4 [52]
Hospital admissions
  QaH Paediatric (< 5 years of age) 4.098 × 10−3 (0.624 × 10−3–13.141 × 10−3)5 [52]
  QaH Adult (≥5 years of age) 2.990 × 10−3 (0.346 × 10−3–11.387 × 10−3)6 [52]
Deaths
  Life expectancy 81.0 years [51]
  QaS Age-specific QALY loss See Additional file 1: Section 5.2.  
  1. Fitted distributions
  2. 1N(725.293, 4.1264
  3. 2N(425.242, 5.2781
  4. 3Gamma(1.57764, 0.0014807)
  5. 4Gamma(1.41075, 0.0010264)
  6. 5Gamma(2.0017, 0.00204726)
  7. 6Gamma(1.60289, 0.00186539)